Today’s Research Reports on VentriPoint Diagnostics, Cotinga Pharmaceuticals, Knight Therapeutics and CanniMed Therapeutics
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
VentriPoint Diagnostics Ltd.
https://rdinvesting.com/news/?ticker=VPT.V
Cotinga Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=COT.V
Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO
CanniMed Therapeutics Inc.
https://rdinvesting.com/news/?ticker=CMED.TO
VentriPoint Diagnostics' stock had no change Friday, to close the day at $0.30. The stock recorded a trading volume of 12,000 shares, which was below its three months average volume of 106,901 shares. In the last year, VentriPoint Diagnostics' shares have traded in a range of 0.17 - 0.42. The share price has gained 79.41% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.305 is greater than its 200-day moving average of $0.28.
Access RDI's VentriPoint Diagnostics Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=VPT.V
On Friday, shares of Cotinga Pharmaceuticals recorded a trading volume of 8,150 shares, which was below the three months average volume of 15,425 shares. The stock ended the day flat at 0.49. The share price has gained 68.97% from its 52 week low with a 52 week trading range of 0.29 - 3.90. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.44 is below its 200-day moving average of $0.85. Shares of Cotinga Pharmaceuticals have fallen approximately 55.45 percent year-to-date.
Access RDI's Cotinga Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=COT.V
Knight Therapeutics' stock moved 1.12% lower Friday, to close the day at $7.96. The stock recorded a trading volume of 35,240 shares, which was below its three months average volume of 166,471 shares. In the last year, Knight Therapeutics' shares have traded in a range of 7.38 - 10.75. The stock is currently trading 25.95% below its 52 week high. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.82 is below its 200-day moving average of $7.95. Shares of the company are trading at a Price to Earnings ratio of 66.33. Shares of Knight Therapeutics have fallen approximately 4.21 percent year-to-date.
Access RDI's Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO
On Friday, shares of CanniMed Therapeutics recorded a trading volume of 22,143 shares, which was below the three months average volume of 290,152 shares. The stock ended the day 2.16% lower at 29.00. The share price has gained 296.17% from its 52 week low with a 52 week trading range of 7.32 - 46.00. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $33.67 is greater than its 200-day moving average of $26.64. Shares of the company are trading at a Price to Earnings ratio of 202.80. Shares of CanniMed Therapeutics have gained approximately 28.60 percent year-to-date.
Access RDI's CanniMed Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CMED.TO
Our Actionable Research on VentriPoint Diagnostics Ltd. (TSXV :VPT.V), Cotinga Pharmaceuticals Inc. (TSXV :COT.V), Knight Therapeutics Inc. (TSX :GUD.TO) and CanniMed Therapeutics Inc. (TSX :CMED.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute
SOURCE: RDInvesting.com
